Hepatitis B transplantation: special conditions.

Area of Science:

• Hepatology
• Virology
• Transplantation Immunology

Background:

• Hepatitis B virus (HBV) infection can present as a coinfection with other viral agents like hepatitis C virus (HCV) and hepatitis D virus (HDV).
• Coinfections and secondary conditions such as hepatocellular carcinoma significantly influence treatment outcomes and the success of liver transplantation.
• Understanding the interplay of these viral coinfections is crucial for managing liver disease and improving patient prognosis.

Purpose of the Study:

• To review the impact of HBV coinfections on treatment and liver transplantation.
• To analyze the outcomes of liver transplantation in patients with HBV coinfections.
• To discuss current and future therapeutic strategies for managing HBV coinfections and post-transplant recurrence.

Main Methods:

• Literature review of studies on HBV coinfections (HBV/HCV, HBV/HDV) and their impact on liver transplantation.
• Analysis of patient data regarding recurrence rates and survival post-transplantation.
• Evaluation of treatment modalities for HBV coinfections, including hepatitis B immune globulin and interferon.

Main Results:

• Patients with HBV and HDV coinfection show a lower risk of HBV recurrence post-transplantation compared to HBV-alone cases.
• HBV/HCV coinfected patients demonstrate a higher 5-year survival rate after liver transplantation.
• Current treatments for coinfection mirror those for HBV alone, with varying efficacy of hepatitis B immune globulin and interferon.

Conclusions:

• Coinfection with HDV or HCV influences liver transplant outcomes, potentially offering protective effects against HBV recurrence and improving long-term survival.
• Treatment strategies for coinfections are largely similar to HBV monoinfection, but require further optimization.
• Post-transplant recurrence and reinfection present significant clinical challenges necessitating novel therapeutic approaches and ongoing research.